Skip to main content

Table 1 Overview of assessments shortly after intranodal vaccination

From: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

AssessmentOptions
Vaccination sideLeft, right, not performed
Visual inspection of vaccination siteNo abnormalities, erythema, blisters, other …
Echo-guided inspection of vaccination siteNo abnormalities, pathological enlarged lymph node (… mm), other …
Time of vaccinationhh:mm
Vaccination in middle of lymph nodeWith certainty in middle, doubtful
Physical examination 5 and 50–70 min after procedureRespiratory rate (RR) and pulse rate/min.